Growing use of novel HER2-directed therapies demands careful patient selection and skilled recognition of pulmonary toxicities to minimize unnecessary morbidity and mortality. Expand your knowledge by exploring evidence-based strategies to improve early recognition and best practices in the management of drug-induced interstitial lung disease (ILD)/pneumonitis to optimize outcomes in patients with HER2+ metastatic breast cancer. In the second Clinical Case Challenge in this series, test your skills in routine monitoring, identification, and management of ILD in patients treated with novel HER2-directed therapies. See how you stack up against your peers on the leaderboard and receive real-time evidence-based expert commentary from a leading breast oncologist.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/interstitial-lung-disease-associated-anti-her2-therapy-older-patient
- Start Date: 2025-01-31 06:00:00
- End Date: 2025-01-31 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 31000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 4714.29 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all